



Department of Health

ANDREW M. CUOMO
Governor

HOWARD A. ZUCKER, M.D., J.D.
Commissioner

SALLY DRESLIN, M.S., R.N.
Executive Deputy Commissioner

March 3, 2020

Revised: Clarification #3 for 2020 Quality Assurance Reporting Requirements Technical Specifications

Dear Colleague,

This letter contains information about edits incorporated into the 2020 NYS Patient-Level Detail (PLD) File Specifications.

The updated PLD specifications are posted on our Managed Care [Information for Health Plans](#) page.

The following edits were made to the 2020 NYS PLD File Specifications:

Product: Commercial

General Edit

- Revised Member ID Data Element Specification

Clarification:

- Report the health plan's unique member ID if using the same internal member ID for claims processing and HEDIS and QARR PLD reporting.
- If the health plan uses a different ID for claims processing than the ID the HEDIS vendor uses for quality reporting, the health plan must work with vendor to submit the plan's internal unique member identifier.

Please note: If vendor is unable to resolve this issue for the 2020 reporting year, MCOs may request a one-year exemption with the expectation that this issue will be resolved for the 2021 reporting year.

Products: Commercial and Medicaid

Updated Measures

- Updated age stratifications to align with HEDIS 2020 Technical Specifications, "1 – 11 years"
 - Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)
 - Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)

- Updated age stratifications to align with HEDIS 2020 Technical Specifications, “6-17, 18-64, 65+”
 - Follow-Up After Emergency Department Visit for Mental Illness (FUM)
 - Follow-Up After Hospitalization for Mental Illness (FUH)
- Edited specifications to account for multi-reporting, increased field length to “2”.
- Removed “total” rows
 - Follow-Up After High Intensity Care for Substance Use Disorder (FUI)

Added HEDIS indicators

- The percentage of children and adolescents on antipsychotics who received blood glucose testing
- The percentage of children and adolescents on antipsychotics who received cholesterol testing
 - Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)

Products: Commercial, Medicaid, and MarketPlace

General Edits

- Adjusted Column Lengths
- 'O' includes, but is not limited to: missing, refused, and unspecified
- Updated the specification for the “sex” field to include:

Updated Measures

- Edited specifications to account for event-level reporting (multi-reporting), increased field length to “2”.
- Edited age stratifications to “3 months – 17 years”
 - Appropriate Testing for Pharyngitis (CWP)
 - Appropriate Treatments for Upper Respiratory Infection (URI)
 - Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)

If there are any questions about the above edits, please email at nysqarr@health.ny.gov.

Sincerely,



Paloma Luisi, MPH
 Director
 Bureau of Quality Measurement &
 Evaluation

CC: L. Cogan
 K. Egglefield